How much funding has AgomAb Therapeutics NV raised?

AgomAb Therapeutics NV has raised $337.8M in total funding, most recently a Series D round.

Who are AgomAb Therapeutics NV's investors?

AgomAb Therapeutics NV's investors include Fidelity Management, Pfizer Ventures, Novo Holdings A/S, Asabys Partners, V-Bio Ventures, Canaan Partners.

When was AgomAb Therapeutics NV founded?

AgomAb Therapeutics NV was founded in 2017.

Where is AgomAb Therapeutics NV headquartered?

AgomAb Therapeutics NV is headquartered in Antwerp, Belgium.

What industry is AgomAb Therapeutics NV in?

AgomAb Therapeutics NV operates in Biotech, Healthcare.

How many employees does AgomAb Therapeutics NV have?

AgomAb Therapeutics NV has 11-50 employees.

AgomAb Therapeutics NV

formerly Agomab TherapeuticsIPO

Agomab Therapeutics – building a company focused on treating fibrosis

Public · Antwerp, Belgium · Founded 2017 · $337.8M raised

Biotech

Healthcare

Headquarters: Antwerp
Employees: 11–50
Founded: 2017
Business Model: B2B
Website: agomab.com

Total Funding: $337.8M
Last Round: $89.0M Series DJan 2024
Rounds: 7
Type: Public

About

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies targeting the HGF/MET signaling pathway for fibrotic and inflammatory diseases. Founded in 2017 and headquartered in Ghent, Belgium, the company's lead programs focus on conditions such as IBD, liver fibrosis, and AKI, with a pipeline of engineered agonist antibodies designed to promote tissue regeneration and repair.

Summary

AgomAb Therapeutics NV is a Biotech company based in Antwerp, Belgium, founded in 2017. It has raised $337.8M in total across 7 rounds, most recently a $89.0M Series D round in Jan 2024. Investors include Fidelity Management, Pfizer Ventures and Novo Holdings A/S.